Impact of hepatitis C virus recombinant form RF1_2k/1b on treatment outcomes within the Georgian national hepatitis C elimination program

2017 ◽  
Vol 48 (1) ◽  
pp. 36-44 ◽  
Author(s):  
Marine Karchava ◽  
Nikoloz Chkhartishvili ◽  
Lali Sharvadze ◽  
Akaki Abutidze ◽  
Natia Dvali ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Outcomes ◽  
Recombinant Form ◽  
Virus Recombinant

Treatment outcomes of hepatitis C virus recombinant form 2k/1b with sofosbuvir based regimens in Georgia

2017 ◽  
Vol 66 (1) ◽  
pp. S302-S303
Author(s):  
M. Zakalashvili ◽  
J. Zarkua ◽  
M. Weizenegger ◽  
J. Bartel ◽  
M. Raabe ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Outcomes ◽  
Recombinant Form ◽  
Virus Recombinant

Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b

2020 ◽  
Author(s):  
Mamuka Zakalashvili ◽  
Jaba Zarkua ◽  
Robert G. Gish ◽  
Maia Zhamutashvili ◽  
Vakhtang Sartania ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Options ◽  
Recombinant Form ◽  
Virus Recombinant

scholarly journals Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2

2019 ◽  
Vol 63 (12) ◽  
Author(s):  
Ernest Asante-Appiah ◽  
Paul Ingravallo ◽  
Patricia McMonagle ◽  
Karin Bystol ◽  
Ellen Xia ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Amino Acid ◽  
Treatment Outcomes ◽  
Cross Talk ◽  
Site Directed Mutagenesis ◽  
Virus Genotype ◽  
Ns5a Inhibitor ◽  
Genotype 2 ◽  
Antiviral Activities

ABSTRACT Hepatitis C virus (HCV) genotype 2 (GT2) represents approximately 9% of all viral infections globally. While treatment outcomes for GT2-infected patients have improved substantially with direct-acting antiviral agents (DAAs) compared to alpha interferon, the presence of polymorphisms in NS5A can impact the efficacy of NS5A inhibitor-containing regimens. Thus, pathways of NS5A resistance were explored in GT2 subtypes using elbasvir, an NS5A inhibitor with broad genotype activity. Resistance selection studies, resistance analysis in NS5A-inhibitor treated virologic failures, and analyses of antiviral activities in replicons bearing a panel of GT2 subtype sequences and amino acid substitutions introduced by site-directed mutagenesis were performed to define determinants of inhibitor susceptibility. Elbasvir showed differential antiviral activities in replicons bearing GT2 sequences. The 50% effective concentration (EC50) values for replicons bearing reference NS5A sequences for GT2a and GT2b were 0.003 and 3.4 nM, respectively. Studies performed with recombinant replicons demonstrated cross talk between amino acid positions 28 and 31. The combination of phenylalanine and methionine at positions 28 and 31, respectively, conferred the highest potency reduction for elbasvir in GT2a and GT2b. This combination was observed in failures seen in the C-SCAPE trial. Addition of grazoprevir, an NS3/4A protease inhibitor, to elbasvir more effectively suppressed the emergence of resistance in GT2 at modest inhibitor concentrations (3× EC90). Ruzasvir, a potent, pan-genotype NS5A inhibitor, successfully inhibited replicons bearing GT2 resistance-associated substitutions (RASs) at positions 28 and 31. The results demonstrate that cross talk between amino acids at positions 28 and 31 in NS5A modulated inhibitor potency and may impact treatment outcomes in some HCV GT2-infected patients.

scholarly journals Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Curtis L. Cooper ◽  
◽  
Daniel Read ◽  
Marie-Louise Vachon ◽  
Brian Conway ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Treatment Outcomes ◽  
Hepatitis C Virus Infection ◽  
Canadian Immigrants

scholarly journals Marijuana Use in Hepatitis C Infection does not Affect Liver Biopsy Histology or Treatment Outcomes

2014 ◽  
Vol 28 (7) ◽  
pp. 381-384 ◽  
Author(s):  
Theresa Liu ◽  
Glen T Howell ◽  
Lucy Turner ◽  
Kimberley Corace ◽  
Gary Garber ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Viral Hepatitis ◽  
Treatment Outcomes ◽  
Sustained Virological Response ◽  
Virological Response ◽  
Antiviral Treatment ◽  
Marijuana Use ◽  
Ottawa Hospital

BACKGROUND: Marijuana smoking is prevalent among hepatitis C virus-infected patients. The literature assessing the influence of marijuana on liver disease progression and hepatitis C virus antiviral treatment outcomes is conflicting.METHODS: The authors evaluated hepatitis C virus RNA-positive patients followed at The Ottawa Hospital Viral Hepatitis Clinic (Ottawa, Ontario) from 2000 to 2009. Using The Ottawa Hospital Viral Hepatitis Clinic database and charts, information regarding demographics, HIV coinfection, alcohol use, liver biopsy results, treatment outcomes and self-reported marijuana use was extracted. Biopsy characteristics and hepatitis C virus antiviral treatment outcomes were assessed for association with categorized marijuana use by adjusted logistic regression; covariates were specified according to clinical relevance a priori.RESULTS: Information regarding marijuana use was available for 550 patients, 159 (28.9%) of whom were using marijuana at the time of first assessment. Biopsy fibrosis stage and marijuana use data were available for 377 of these 550 (F0-2=72.3%). Overall, marijuana use did not predict fibrosis stage, inflammation grade or steatosis. Sustained virological response and marijuana use data were available for 359 of the 550 cohort participants; a total of 211 (58.8%) achieved a sustained virological response. Marijuana use was not associated with premature interruption of therapy for side effects, the likelihood of completing a full course of therapy or sustained virological response.CONCLUSION: Marijuana use did not influence biopsy histology or alter key hard outcomes of hepatitis C virus antiviral therapy.

scholarly journals Gender Differences in Hepatitis C Virus (HCV) Treatment Outcomes With Peginterferon (pegIFN) Plus Ribavirin (RBV): An Analysis of the IDEAL Study

2011 ◽  
Vol 140 (5) ◽  
pp. S-946
Author(s):  
Kara Loubser ◽  
Eric J. Lawitz ◽  
Mitchell L. Shiffman ◽  
John McHutchison ◽  
Andrew J. Muir ◽  
...  
Keyword(s):  
Gender Differences ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Outcomes ◽  
Hcv Treatment ◽  
Ideal Study ◽  
The Ideal

Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance‐associated substitutions

2020 ◽  
Vol 40 (11) ◽  
pp. 2660-2671
Author(s):  
Julia Dietz ◽  
Johannes Vermehren ◽  
Katrin Matschenz ◽  
Peter Buggisch ◽  
Hartwig Klinker ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Outcomes ◽  
Virus Genotype ◽  
Genotype 1A

scholarly journals Capacity Enhancement of Hepatitis C Virus Treatment through Integrated, Community-Based Care

2008 ◽  
Vol 22 (1) ◽  
pp. 27-32 ◽  
Author(s):  
Warren D Hill ◽  
Gail Butt ◽  
Maria Alvarez ◽  
Mel Krajden
Keyword(s):  
Public Health ◽  
British Columbia ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Outcomes ◽  
Antiviral Therapy ◽  
Public Health Nurse ◽  
Geographical Information ◽  
Community Based ◽  
Health Nurse

BACKGROUND: An estimated 250,000 Canadians are infected with the hepatitis C virus (HCV). The present study describes a cohort of individuals with HCV referred to community-based, integrated prevention and care projects developed in British Columbia. Treatment outcomes are reported for a subset of individuals undergoing antiviral therapy at four project sites.METHODS: Four demonstration projects based on a public health nurse and physician partnership were established in rural and small urban centres in British Columbia. Comprehensive medical assessments determined whether individuals received treatment, or counselling and education. Outcomes of the treatment group were compared with published randomized controlled trials. Client demographics were mapped using geographical information systems applications.RESULTS: A total of 1795 individuals were referred to the clinics for medical assessment between Septmber 2001 and December 2005. After assessment, 26% were eligible for therapy, while 74% received counselling and education. Wait times decreased annually, with one-half of all referrals assessed within 30 days. Combination antiviral therapy was initiated in 363 clients with interferon plus ribavirin (n=36) or pegylated interferon plus ribavirin (n=327). Treatment outcomes were available for 205 individuals. The overall rate of sustained virological response was 61% (126 of 205 individuals). The number of individuals assessed at each site represented, on average, 20% of the total cumulative reported HCV cases in the catchment areas.DISCUSSION: The study findings illustrate how a public health nurse and physician partnership can service a population with complex medical needs while simultaneously increasing local capacity. Treatment outcomes were comparable with published clinical trials.

scholarly journals Treatment Outcomes in a Centralized Specialty Clinic for Hepatitis C Virus Are Comparable with Those from Clinical Trials

2006 ◽  
Vol 20 (2) ◽  
pp. 87-90 ◽  
Author(s):  
Kelly DE Kaita ◽  
Stephen Wong ◽  
Eberhard Renner ◽  
Gerald Y Minuk
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Viral Hepatitis ◽  
Treatment Outcomes ◽  
Antiviral Therapy ◽  
Interferon Alpha ◽  
Pegylated Interferon ◽  
Urban Centre ◽  
Pegylated Interferon Plus Ribavirin ◽  
Viral Responses

BACKGROUND: Outcomes from industry-sponsored registration trials are often considered to be more favourable than those achieved in clinical practice because patients involved in the former are highly selected and supported, but it is not known if this impression is valid.OBJECTIVE: To determine the outcome of hepatitis C virus (HCV)-infected patients who received therapies for chronic HCV in a single urban centre and compare the results with those derived from contemporary, industry-sponsored trials.DESIGN: Retrospective chart review of HCV-infected patients referred to the Viral Hepatitis Investigative Unit in Winnipeg, Manitoba, between 1998 and 2003.METHODS: The Viral Hepatitis Investigative Unit database was used to identify all referred patients with positive anti-HCV antibodies. Charts were reviewed for the following data: patient demographics; viral genotype; indications and contraindications to treatment; treatment type; and outcome of antiviral therapy.RESULTS: For 1800 anti-HCV positive patients identified, 1078 charts were available for review. Of these patients, the mean age was 47 years (range 11 years to 90 years) and 53% were men. Genotype 1 was the most common (65%). A total of 331 patients (31%) had received antiviral therapy. The sustained viral responses were similar to those described in industry-sponsored registration trials. Specifically, the sustained viral responses for interferon-alpha monotherapy (n=81) was 22.2%, interferon-alpha plus ribavirin (n=180) 44.4%, pegylated interferon monotherapy (n=38) 44.7% and pegylated interferon plus ribavirin (n=24) 54.2%.CONCLUSION: HCV treatment outcomes from a single urban centre were similar to those described in industry-sponsored registration trials despite the high selection and support provided to patients enrolled in the latter studies.

Sign in / Sign up

Export Citation Format

Share Document